For the analysis of hydrocortisone released from the tablets, 2690 high performance liquid chromatography equipment (HPLC) and a 484 diode array detector (DAD) (Waters, Milford, MA, USA) were used. A Sartorius CP224S Scale (Goettegen, Germany) was used with a precision of ±0.0001. The pH measurements were performed on a GLP22 Crison pH meter (Barcelona, Spain). Dissolution tests were carried out at 37 °C in a USP dissolution apparatus II (paddle) using a Sotax AT 7smart Dissolution Tester (Nordring, Switzerland) in accordance with the US and European Pharmacopeia with paddle method.
Chromatographic separation was achieved on a C-18 (50 mm × 4.6 mm, 3.5 µm) Waters XBridge column (Waters Corporation, Milford, MA, USA), using an isocratic mode with a 77:23 (H2O:acetonitrile) mobile phase at a flow rate of 0.6 mL/min. A sample aliquot of 10 μL was injected into the column at 30 °C and the working wavelength was 245 nm [24,25,26,27].
An in vitro drug release study from tablets, to simulate the physiological conditions at the buccal mucosa level, was carried out. The dissolution profiles of the tablet samples were obtained in 500 mL of simulated saliva (pH 6.75). The paddle rotational speed was set at 100 rpm at a constant temperature bath of 37.0 ± 0.5 °C. The dissolution experiment was initiated by placing the sample in the dissolution vessel. Sample aliquots of 5 mL were withdrawn at specific intervals (0, 1, 3, 5, 24, 48, and 72 h) replaced with an equal volume of fresh medium. The aliquots were filtered through a 0.45 µm PTFE filter prior to the injection in the HPLC system (Method validation in the Supplementary Materials, Figure S1) [24,28].
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.